14.09.2012 - Cosmo's new anti-diarrhoea formulation of rifamycin meets the Phase III trial primary endpoints.
Cosmo Pharmaceuticals S.p.A. from Lainate (Lombardy) announced on 12 September the top-line results of a Phase III clinical trial with rifamycin SV MMX. Its US licensee Santarus, Inc. from San Diego (US) conducted a multicentre, randomised, placebo-controlled study where patients with traveller’s diarrhoea were treated with 800 mg rifamycin SV MMX a day for three consecutive days. The scored primary endpoints were a reduction of the time to last unformed stool (TLUS, down from 68 hours in placebo-group to 46 hours in active drug-group) and the clinical cure (56,9% placebo, 81,4% active treatment).
Cosmo is now awaiting results of a second Phase III study conducted by German Dr. Falk Pharma GmbH from Freiburg. Here the drug is tested against ciprofloxacin treatment. The results are expected in H2/2012. Milestone payments from Santarus will be due at regulatory acceptance as well as at the successful conclusion of a Phase III trial in another indication. Cosmo is also having an interest in sales royalties which amount to more than 20% – plus certain revenue milestones.
Rifamycin SV is a non-systemic antibiotic which has been used for years intravenously and intramuscularly. Combined with Cosmos’s MMX delivery technology, the antibiotic now passes the upper gastrointestinal tract without degradation for final release in the colon. The lipophilic and amphiphilic matrices disperse within a hydrophilic matrix and are coated with gastro-resistant polymers. Cosmo, Santarus and Swiss Ferring Pharmaceuticals S.A. are also working together on another MMX drug named Ultesa/Uceris. That drug offers potentially improved side-effect profiles compared with established systemic corticosteroids used to treat ulcerative colitis. However, signs were bleak when the approval of the drug in the Netherlands failed in August.
29.08.2014 Just a week ago, Glaxosmithkline defused the WHO’s claim that an Ebola vaccine could be ready by 2015. Now, the British company’s own candidate vaccine is to be rushed to human trials with the help of funding from an international consortium.
24.08.2014 Germany's Morphosys is licensing a preclinical bi-specific antibody for the treatment of prostate cancer from Emergent Biosolutions. The US developer will rake in up to €138m for the commercialisation rights to the compound.
20.08.2014 Biopharmaceutical contract manufacturer Fujifilm Diosynth Biotechnologies is expanding its cell culture manufacturing capacity further with a new 2,000l single-use bioreactor at the company’s site in Billingham, UK.
08.08.2014 Boehringer Ingelheim is walking away from Swedish Orexo's prostaglandin inhibition project OX-MPI. Germany's largest researching pharmaceutical company had been responsible for the project's research and development since 2005.